Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selicrelumab and Emactuzumab in Advanced Solid Tumors
NCT02760797Phase 1Completed
- Sponsor
- Roche
- Start
- May 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of selicrelumab in triple negative breast cancer (TNBC), ovarian cancer, gastric cancer (GC) and 4 more (2 arms), sponsored by Roche. Primary endpoint: Dose-Limiting Toxicities at 6 weeks. Started May 2016; status: completed.
02
Drugs
selicrelumab
03
Conditions
triple negative breast cancer (TNBC)ovarian cancergastric cancer (GC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02760797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760797.